Latest Antivirals Stories
OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin CORK, Ireland, April 2, 2014 /PRNewswire/ -- Janssen R&D Ireland
ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug.
Markets Research Reports.biz added deep and professional market research reports on "Global Cloud Computing: Infrastructure, Platforms, and Services 2014 - 2019" Market Analysis and
Markets Research Reports.biz added deep and professional market research reports on "Global Cancer Vaccines Competitor Analysis And Market Research" Market Analysis and Overview.
Markets Research Reports.biz added deep and professinal market research reports on "Global Endoscopy Market Report 2014" Market Analysis and Overview. Albany,
CORK, Ireland, March 24, 2014 /PRNewswire/ -- New data from the clinical development program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 chronic hepatitis C virus (HCV)
NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in
ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc.
-- SVR(12) rates of 99 percent with and without ribavirin were achieved in genotype 1b patients new to treatment BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results
ResearchMoz include new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Industry Size, Shares, Growth, Trends and Forecast 2019" to its huge collection
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.